Dietary factors regulate cytokines in murine models of systemic lupus erythematosus

Autoimmunity Reviews

Volumn 11, Issue 1, 2011, Pages 22-27

  Hsieh, Chia Chien ^a   Lin, Bi Fong ^a  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Autoantibodies, cytokines; Autoimmunity; Diet; Inflammation; Proteinuria; Systemic lupus erythematosus (SLE); Th1 Th2 balance; Vitamin

Indexed keywords

ALPHA TOCOPHEROL; AUTOANTIBODY; OMEGA 3 FATTY ACID; OMEGA 6 FATTY ACID; RETINOL; VITAMIN D;

ANTIBODY PRODUCTION; CALORIC RESTRICTION; CYTOKINE PRODUCTION; DIET; HUMAN; IMMUNOMODULATION; LIFESTYLE MODIFICATION; NONHUMAN; PROTEINURIA; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; TRADITIONAL MEDICINE;

ANIMALS; AUTOANTIBODIES; CALORIC RESTRICTION; CYTOKINES; DIET THERAPY; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; IMMUNOMODULATION; LUPUS ERYTHEMATOSUS, SYSTEMIC; MICE; TREATMENT OUTCOME; VITAMINS;

EID: 80855143593     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2011.06.009     Document Type: Review

References (95)

1. Mackay I.R. Clustering and commonalities among autoimmune diseases. J Autoimmun 2009, 33:170-177.
2. Shapira Y., Agmon-Levin N., Shoenfeld Y. Defining and analyzing geoepidemiology and human autoimmunity. J Autoimmun 2010, 34:J168-J177.
3. Gershwin M.E., Borchers A.T., Keen C.L. Phenotypic and functional considerations in the evaluation of immunity in nutritionally compromised hosts. J Infect Dis 2000, 182:S108-S114.
4. Chiu Y.-M., Lai C.-H. Nationwide population-based epidemiologic study of systemic lupus erythematosus in Taiwan. Lupus 2010, 19:1250-1255.
5. Selmi C., Tsuneyama K. Nutrition, geoepidemiology, and autoimmunity. Autoimmun Rev 2010, 9:A267-A270.
6. Fernandes G., Yunis E.J., Good A. Influence of diet on survival of mice. Proc Natl Acad Sci USA 1976, 73:1279-1283.
7. Muthukumar A.R., Jolly C.A., Zaman K., Fernandes G. Caloric restiction decreases prolinflammatory cytokines and polymeric Ig receptor expression in the submandibular glands of autoimmune prone (NZB×NZW) F1 mice. J Clin Immunol 2000, 20:354-361.
8. Jolly C.A., Muthukumar A., Reddy Avula C.P., Troyer D., Fernandes G. Life span is prolonged in food-restricted autoimmune-prone (NZB×NZW)F(1) mice fed a diet enriched with (n-3) fatty acids. J Nutr 2001, 131:2753-2760.
9. Harbige L.S. Fatty acids, the immune response, and autoimmunity: a question of n-6 essentiality and the balance between n-6 and n-3. Lipids 2003, 38:323-341.
10. Leiba A., Amital H., Gershwin M.E., Shoenfeld Y. Diet and lupus. Lupus 2001, 10:246-248.
11. Lin B.F., Jeng S.J., Chiang B.L., Huang C.C. Dietary fat affects lipids and anti-cardiolipin antibody levels in autoimmune-prone NZB/W F1 mice. Br J Nutr 1997, 77:657-669.
12. Fernandes G. Dietary lipids and risk of autoimmune disease. Clin Immunol Immunopathol 1994, 72:193-197.
13. Lin B.F., Jeng S.J. Effects of dietary frying oil on lipids and anti-cardiolipin antibody levels in autoimmune-prone NZB/W F1 mice. Nutr Res 1997, 17:1047-1052.
14. Chandrasekar B., Troyer D.A., Venkatraman J.T., Fernandes G. Dietary omega-3 lipids delay the onset and progression of autoimmune lupus nephritis by inhibiting transforming growth factor beta mRNA and protein expression. J Autoimmun 1995, 8:381-393.
15. Chang S.C., Chiang B.L., Wu W.M., Lin B.F. Different dietary fats influence serum and tissue lipids and anti-cardiolipin antibody levels in autoimmune-prone NZB/W F1 mice. Br J Nutr 1999, 81:331-340.
16. Reifen R., Amital H., Blank M., Sklan D., Berkovich Z., Gershwin E., et al. Linseed oil suppresses the anti-beta-2-glycoprotein-I in experimental antiphospholipid syndrome. J Autoimmun 2000, 15:381-385.
17. Gershwin M.E., Lentz D.R., Beach R.S., Hurley L.S. Nutritional factors and autoimmunity. IV. Dietary vitamin A deprivation induces a selective increase in IgM autoantibodies and hypergammaglobulinemia in New Zealand Black Mice. J Immunol 1984, 133:222-226.
18. Kinoshita K., Yoo B.S., Nozaki Y., Sugiyama M., Ikoma S., Ohno M., et al. Retinoic acid reduces autoimmune renal injury and increases survival in NZB/W F1 mice. J Immunol 2003, 170:5793-5798.
19. Nozaki Y., Yamagata T., Yoo B.S., Sugiyama M., Ikoma S., Kinoshita K., et al. The beneficial effects of treatment with all-trans-retinoic acid plus corticosteroid on autoimmune nephritis in NZB/W F mice. Clin Exp Immunol 2005, 139:74-83.
20. Pérez de Lema G., Jucio-Cazańa F.J., Molina A., Luckow B., Schmid H., de Wit C., et al. Retinoic acid treatment protects MRL/lpr lupus mice from the development of glomerular disease. Kidney Int 2004, 66:1018-1028.
21. Zhou X., Kong N., Wang J., Fan H., Zou H., Horwitz D., et al. Cutting edge: all-trans retinoic acid sustains the stability and function of natural regulatory T cells in an inflammatory milieu. J Immunol 2010, 185:2675-2679.
22. Deluca H.F., Cantorna M.T. Vitamin D: its role and uses in immunology. FASEB J 2001, 15:2579-2585.
23. Adorini L. Immunomodulatory effects of vitamin D receptor ligands in autoimmune diseases. Int Immunopharmacol 2002, 2:1017-1028.
24. Pelajo C.F., Lopez-Benitez J.M., Miller L.C. Vitamin D and autoimmune rheumatologic disorders. Autoimmun Rev 2010, 9:507-510.
25. 3 attenuates the expression of experimental murine lupus of MRL/l mice. Autoimmunity 1992, 12:143-148.
26. Wüthrich R.P., Fan X., Ritthaler T., Sibalic V., Yu D.J., Loffing J., et al. Enhanced osteopontin expression and macrophage infiltration in MRL-Fas(lpr) mice with lupus nephritis. Autoimmunity 1998, 28:139-150.
27. Doria A., Zen M., Canova M., Bettio S., Bassi N., Nalotto L., et al. SLE diagnosis and treatment-when early is early. Autoimmun Rev 2010, 10:55-60.
28. Kurien B.T., Scofield R.H. Autoimmunity and oxidatively modified autoantigens. Autoimmun Rev 2008, 7:567-573.
29. Ortona E., Margutti P., Matarrese P., Franconi F., Malorni W. Redox state, cell death and autoimmune diseases: a gender perspective. Autoimmun Rev 2008, 7:579-584.
30. Hsieh C.C., Lin B.F. The effects of vitamin E supplementation on autoimmune-prone NZB/W F1 mice fed the oxidized oil diet. Br J Nutr 2005, 93:655-662.
31. Harris S.G., Padilla J., Koumas L., Ray D., Phipps R.P. Prostaglandins as modulators of immunity. Trends Immunol 2002, 23:144-150.
32. Hsieh C.C., Lin B.F. Opposite effects of low- and high-dose supplementation of vitamin E on survival of MRL/lpr mice. Nutrition 2005, 21:940-948.
33. Hsieh C.C., Huang C.J., Lin B.F. Low and high levels of α-tocopherol exert opposite effects on IL-2 possibly through the modulation of PPARγ, IκBα and apoptotic pathway in activated splenocytes. Nutrition 2006, 22:433-440.
34. Rubtsov A.V., Rubtsova K., Kappler J.W., Marrack P. Genetic and hormonal factors in female-biased autoimmunity. Autoimmun Rev 2010, 9:494-498.
35. Jiang B., Sun L., Hao S., Li X., Xu Y., Hou Y. Estrogen modulates bone marrow-derived DCs in SLE murine model-(NZB×NZW) F1 female mice. Immunol Invest 2008, 37:227-234.
36. Inui A., Ogasawara H., Naito T., Sekigawa I., Takasaki Y., Hayashida Y., et al. Estrogen receptor expression by peripheral blood mononuclear cells of patients with systemic lupus erythematosus. Clin Rheumatol 2007, 26:1675-1678.
37. Li J., McMurray R.W. Effects of estrogen receptor subtype-selective agonists on autoimmune disease in lupus-prone NZB/NZW F1 mouse model. Clin Immunol 2007, 123:219-226.
38. Morito K., Aomori T., Hirose T., Kinjo J., Hasegawa J., Ogawa S., et al. Interaction of phytoestrogens with estrogen receptors alpha and beta (II). Biol Pharm Bull 2002, 25:48-52.
39. Velasquez M.T., Bhathena S.J. Dietary phytoestrogens: a possible role in renal disease protection. Am J Kidney Dis 2001, 37:1056-1068.
40. Hong Y.H., Wang T.C., Huang C.J., Cheng W.Y., Lin B.F. Soy isoflavones supplementation alleviates disease severity in autoimmune-prone MRL-lpr/lpr mice. Lupus 2008, 17:814-821.
41. Hong Y.H., Huang C.J., Wang S.C., Lin B.F. The ethyl acetate extract of alfalfa sprout ameliorates disease severity of autoimmune-prone MRL-lpr/lpr mice. Lupus 2009, 18:206-215.
42. Hong Y.H., Chao W.W., Chen M.L., Lin B.F. Ethyl acetate extracts of alfalfa (Medicago sativa L.) sprouts inhibit lipopolysaccharide-induced inflammation in vitro and in vivo. J Biomed Sci 2009, 14:64-75.
43. Akaogi J., Barker T., Kuroda Y., Nacionales D.C., Yamasaki Y., Stevens B.R., et al. Role of non-protein amino acid L-canavanine in autoimmunity. Autoimmun Rev 2006, 5:429-435.
44. Schoenroth L.J., Harta D.A., Pollardb K.M., Fritzlera M.J. The effect of the phytoestrogen coumestrol on the NZB/W F1 murine model of systemic lupus. J Autoimmun 2004, 23:323-332.
45. Auborn K.J., Qi M., Yan X.J., Teichberg S., Chen D., Madaio M.P., et al. Lifespan is prolonged in autoimmune-prone (NZB/NZW) F1 mice fed a diet supplemented with indole-3-carbinol. J Nutr 2003, 133:3610-3613.
46. Lai N.S., Lin R.H., Lai R.S., Kun U.C., Leu S.C. Prevention of autoantibody formation and prolonged survival in New Zealand Black/New Zealand White F1 mice with an ancient Chinese herb, Ganoderma tsugae. Lupus 2001, 10:461-465.
47. Furuya Y., Kawakita T., Nomoto K. Immunomodulating effect of a traditional Japanese medicine, Hachimi-jio-gan (Ba-Wei-Di-Huang-Wan), on Th1 predominance in autoimmune MRL/MP-lpr/lpr mice. Int Immunopharmacol 2001, 1:551-559.
48. 2 in peritoneal macrophages is inhibited by Andrographis paniculata, Angelica sinensis and Morus alba ethyl acetate fractions. J Ethnopharmacol 2009, 122:68-75.
49. Ehrenfeld M. Geoepidemiology: the environment and spondyloarthropathies. Autoimmun Rev 2010, 9:A325-A329.
50. Borchers A.T., Uibo R., Gershwin M.E. The geoepidemiology of type 1 diabetes. Autoimmun Rev 2010, 9:A355-A365.
51. Brooks W.H., Le Dantec C., Pers J.O., Youinou P., Renaudineau Y. Epigenetics and autoimmunity. J Autoimmun 2010, 34:J207-J219.
52. Leung P.S., Shu S.A., Kenny T.P., Wu P.Y., Tao M.H. Development and validation of gene therapies in autoimmune diseases: epidemiology to animal models. Autoimmun Rev 2010, 9:A400-A405.
53. Maverakis E., Miyamura Y., Bowen M.P., Correa G., Ono Y., Goodarzi H. Light, including ultraviolet. J Autoimmun 2010, 34:J247-J257.
54. Deane S., Teuber S.S., Gershwin M.E. The geoepidemiology of immune thrombocytopenic purpura. Autoimmun Rev 2010, 9:A342-A349.
55. Chang C., Gershwin M.E. Drugs and autoimmunity-a contemporary review and mechanistic approach. J Autoimmun 2010, 34:J266-J275.
56. Bhat A., Naguwa S., Cheema G., Gershwin M.E. The epidemiology of transverse myelitis. Autoimmun Rev 2010, 9:A395-A399.
57. Powell J.J., Faria N., Thomas-McKay E., Pele L.C. Origin and fate of dietary nanoparticles and microparticles in the gastrointestinal tract. J Autoimmun 2010, 34:J226-J233.
58. Prieto S., Grau J.M. The geoepidemiology of autoimmune muscle disease. Autoimmun Rev 2010, 9:A330-A334.
59. Lleo A., Invernizzi P., Gao B., Podda M., Gershwin M.E. Definition of human autoimmunity-autoantibodies versus autoimmune disease. Autoimmun Rev 2010, 9:A259-A266.
60. Arnson Y., Shoenfeld Y., Amital H. Effects of tobacco smoke on immunity, inflammation and autoimmunity. J Autoimmun 2010, 34:J258-J265.
61. Borchers A.T., Naguwa S.M., Keen C.L., Gershwin M.E. The implications of autoimmunity and pregnancy. J Autoimmun 2010, 34:J287-J299.
62. Invernizzi P. Geoepidemiology of autoimmune liver diseases. J Autoimmun 2010, 34:J300-J306.
63. Chang C. The immune effects of naturally occurring and synthetic nanoparticles. J Autoimmun 2010, 34:J234-J246.
64. Berkun Y., Padeh S. Environmental factors and the geoepidemiology of juvenile idiopathic arthritis. Autoimmun Rev 2010, 9:A319-A324.
65. Zeki A.A., Schivo M., Chan A.L., et al. Geoepidemiology of COPD and idiopathic pulmonary fibrosis. J Autoimmun 2010, 34:J327-J338.
66. Stojanovich L. Stress and autoimmunity. Autoimmun Rev 2010, 9:A271-A276.
67. Segelmark M., Hellmark T. Autoimmune kidney diseases. Autoimmun Rev 2010, 9:A366-A371.
68. Chen M., Daha M.R., Kallenberg C.G. The complement system in systemic autoimmune disease. J Autoimmun 2010, 34:J276-J286.
69. Mavragani C.P., Moutsopoulos H.M. The geoepidemiology of Sjogren's syndrome. Autoimmun Rev 2010, 9:A305-A310.
70. Sands J., Tuscano J.M. Geoepidemiology and autoimmune manifestations of lymphoproliferative disorders. Autoimmun Rev 2010, 9:A335-A341.
71. Biggioggero M., Meroni P.L. The geoepidemiology of the antiphospholipid antibody syndrome. Autoimmun Rev 2010, 9:A299-A304.
72. Hemminki K., Li X., Sundquist J., Sundquist K. The epidemiology of Graves' disease: evidence of a genetic and an environmental contribution. J Autoimmun 2010, 34:J307-J313.
73. Logan I., Bowlus C.L. The geoepidemiology of autoimmune intestinal diseases. Autoimmun Rev 2010, 9:A372-A378.
74. Tomer Y. Hepatitis C and interferon induced thyroiditis. J Autoimmun 2010, 34:J322-J326.
75. Round J.L., O'Connell R.M., Mazmanian S.K. Coordination of tolerogenic immune responses by the commensal microbiota. J Autoimmun 2010, 34:J220-J225.
76. Mackay I.R. Travels and travails of autoimmunity: a historical journey from discovery to rediscovery. Autoimmun Rev 2010, 9:A251-A258.
77. Chandran V., Raychaudhuri S.P. Geoepidemiology and environmental factors of psoriasis and psoriatic arthritis. J Autoimmun 2010, 34:J314-J321.
78. Tobon G.J., Youinou P., Saraux A. The environment, geo-epidemiology, and autoimmune disease: rheumatoid arthritis. Autoimmun Rev 2010, 9:A288-A292.
79. Gershwin M.E., Goetzl E.J., Steinberg A.D. Cyclophosphamide: use in practice. Ann Intern Med 1974, 80:531-540.
80. Tonutti E., Visentini D., Bizzaro N. Interpretative comments on autoantibody tests. Autoimmun Rev 2007, 6:341-346.
81. Bizzaro N., Tozzoli R., Shoenfeld Y. Are we at a stage to predict autoimmune rheumatic diseases?. Arthritis Rheum 2007, 56:1736-1744.
82. Youinou P., Pers J.O., Gershwin M.E., Shoenfeld Y. Geo-epidemiology and autoimmunity. J Autoimmun 2010, 34:J163-J167.
83. Mackay I.R. The etiopathogenesis of autoimmunity. Semin Liver Dis 2005, 25:239-250.
84. Chen M., Kallenberg C.G. The environment, geoepidemiology and ANCA-associated vasculitides. Autoimmun Rev 2010, 9:A293-A298.
85. Martin P.I., Malizia A.I., Rewald E. A propos time and autoimmunity. Clin Rev Allergy Immunol 2008, 34:380-384.
86. Borchers A.T., Naguwa S.M., Shoenfeld Y., Gershwin M.E. The geoepidemiology of systemic lupus erythematosus. Autoimmun Rev 2010, 9:A277-A287.
87. Hershko A.Y., Naparstek Y. Autoimmunity in the era of genomics and proteomics. Autoimmun Rev 2006, 5:230-233.
88. Lambert J.F., Nydegger U.E. Geoepidemiology of autoimmune hemolytic anemia. Autoimmun Rev 2010, 9:A350-A354.
89. Hoffmann M.H., Trembleau S., Muller S., Steiner G. Nucleic acid-associated autoantigens: pathogenic involvement and therapeutic potential. J Autoimmun 2010, 34:J178-J206.
90. Meyer A., Levy Y. Chapter 33: geoepidemiology of myasthenia gravis. Autoimmun Rev 2010, 9:A383-A386.
91. Ranque B., Mouthon L. Geoepidemiology of systemic sclerosis. Autoimmun Rev 2010, 9:A311-A318.
92. Meyer N., Misery L. Geoepidemiologic considerations of auto-immune pemphigus. Autoimmun Rev 2010, 9:A379-A382.
93. Milo R., Kahana E. Multiple sclerosis: geoepidemiology, genetics and the environment. Autoimmun Rev 2010, 9:A387-A394.
94. Selmi C. The worldwide gradient of autoimmune conditions. Autoimmun Rev 2010, 9:A247-A250.
95. Shoenfeld Y., Selmi C., Zimlichman E., Gershwin M.E. The autoimmunologist: geoepidemiology, a new center of gravity, and prime time for autoimmunity. J Autoimmun 2008, 31:325-330.